Akanocure Pharmaceuticals, Inc.

WEST LAFAYETTE, IN · Founded 2014 · CIK 0001638067 · Biotech · Private

Small molecule therapeutics for inflammatory and metabolic diseases

akanocure.com →
Grants
$2.4M
4 awards
Sector median: 1
Raised
$1.0M
1 Form D · Mar 2015
139 months since last filing
Contracts
—
No federal contracts on record
Patents
4
3 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$1,000,000
Federal grantNational Science Foundation · Phase I · SBIR Phase I: Novel Stereo-enriched Libraries as Commercial Complex Building Blocks for Facile Development of Biologically Active Compounds on Large Scale$224,996
Federal grant· 1 of 2 same dayNational Science Foundation · Phase I · SBIR Phase I: AK-423: A broad-spectrum antiviral and immunomodulatory agent (COVID-19)$256,000
Federal grant· 2 of 2 same dayNational Science Foundation · Phase II · SBIR Phase II: Multiplex Expansion of the Chiral Carbon Catalog Platform towards Stereo-enriched Non-propionate Chemical Classes and Industrial Applications$949,999
Federal grantNational Science Foundation · Phase II · SBIR Phase II: A Novel Host-Directed Broad-Spectrum Antiviral and Efficient Immunomodulatory Agent Against Coronaviruses: Lead Optimization Studies$1,000,000
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1427Solutions BioMed LLC—$5.0M
1428ALVEOLUS BIO, INC.——
1429IMAGINEERING TECHNOLOGIES INC—$14M
1430Akanocure Pharmaceuticals, Inc.—$1.0M
1431IT Bio, LLC——
1432Jericho Sciences, LLC——
1433Starwise Therapeutics LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 3 related persons
  • Sherine AbdelmawlaDirector · Executive Officer
  • Philip FuchsDirector · Executive Officer
  • Mohammad NoshiDirector · Executive Officer

Patents

USPTO · 3 granted of 4

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.